MicroliefTM Technology Overview

Racing Commissioners International Conference Regulatory Briefing – Emerging Technologies Tampa, FL April 23, 2015

What is Microlief™?

- The Microlief[™] unit consists of one Microcurrent Power Supply snapped on to one pair of Microcurrent Electrode Patches.
- The patches are specifically designed to transmit the mild electrical current generated by the Microcurrent Power Supply.
- The hydrolgel patches are placed on either side of the target/painful area.
- The Microlief[™] unit is activated when the patches make contact with the body. A blinking red light on the Microcurrent Power Supply indicates that current is flowing through the body.




The Product


- Microlief[™] cannot mask serious pain or aggravated lameness.
- MicroliefTM has no ability to "shock" the horse or user.
- MicroliefTM soft tissue therapy stimulates the natural healing process within the body and reduces the need for NSAIDS.
- MicroliefTM is a tool that can be used both to help prevent soft tissue injuries and to noninvasively assist with recovery when soft tissue injuries do occur.

How it Works

How does micro-current technology bring direct pain relief?




The injured cells resist the body's natural electric current, preventing the supply of blood, oxygen and vital nutrients (A). The Painmaster micro-current penetrates the inflamed cells, restoring the essential blood supply, removing cell waste and bringing direct pain relief (B).



The Technology

- System will deliver a sustained flow of low amperage electric current at a fixed frequency using the latest electronics
- Incorporates the combination of using the body as an electrical switch mechanism coupled with a user interface indicator for positive evidence of current flow through the body.
- All features are patented in a diverse range of micro current devices.



The Technology

Intellectual Property:

<u>Patents</u>

- U.S. Patent No. 6,408,211
- U.S. Patent No. 6,606,519
- European Patent Pending No. EP1294443 B1 (19 Countries)
- Canadian Patent Pending No. 2,410,342
- Mexican Patent No. 231986
- Brazil Patent P10111738-6

The Technology



CE

The Microlief[™] MCT Patch is approved as a Class II medical device by the FDA for over-the-counter sales. The company has enjoyed significant success in obtaining approvals internationally as well.

<u>Approvals</u>

- U.S. FDA Class II medical device- K013167
- U.S. FDA Class II medical device- K090042
- U.S. FDA Class II medical device- K130114 OTC Sales
- European Union EC Directive Reg. No. CE594280 (28 Countries).
- P.R. of China SFDA Approval No. 20042261127
- Korea KFDA Approval No. KTC-BAA-140183
- Canada CMDCAS Approval No. 91710
- Brazil Registration No. 59.053.488/0001-68

Clinical Studies

- FDA Approved Protocol Study for Usability completed at Indiana Spine Clinic.
- IRB: St. Vincent Hospital Research and Regulatory Affairs Review Board.
- Aim Shams University Cairo, Egypt Effects of Micro Current Therapy on Post Operative Pain in patients of Total Knee Arthroplasty. Results:60% reduction in pain on Day 1 90% reduction in pain on Day 10.
- Bradley Memorial Hospital Southington, CT Open Study for Fibromyalgia Support Group -Results:73% reported good to significant improvement.
- University of Utrecht Pain Center Netherlands Double blind, Crossover, Placebo Study. Effects of Micro Current Therapy on Chronic Back Pain Results: 100% response to treatment indicating reduction in pain level and dosage and frequency of medication.



- 630,000 units have been distributed through various outlets a/o 12/31/2014.
- No reports of adverse events.
- Average user has noticeable decrease in pain in less than 24 hours.
- Product is approved for distribution in VA Hospitals.


Microlief[™] Product

Benefits:

- Increases the production of ATP.
- Increases protein synthesis.
- Increases oxygenation.
- Increases ion exchange.
- Increases absorption of nutrients.
- Increases elimination of cellular waste products.
- Neutralizes the oscillating polarity of deficient cells.

Opportunity

Microlief[™] provides horseman with a new, natural, nonpharmaceutical way to manage the muscular stress and injuries that occur so often in equestrian sports.



Summary

In the coming years we expect Microlief[™] to become a mainstay in the veterinary and equestrian world for uses as described.

The purpose of this presentation was to help educate both commissioners and investigators about Microlief[™], what it is, how it works, and it's ability to assist in reduction of excessive NASIDS and other pharmaceuticals.

We welcome any guidance from the commissioners on the use of Microlief[™] within the premises of licensed pari-mutual facilities under your jurisdiction.



Thank you for this opportunity.

Are there any questions?

Newmark Confidential